News
TCRX
1.150
-8.73%
-0.110
TScan Therapeutics to present ASGCT meeting poster on CD45-targeted TCR-T therapies
PUBT · 2d ago
Weekly Report: what happened at TCRX last week (0420-0424)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 04/21 21:05
Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (TCRX) and Arcus Biosciences (RCUS)
TipRanks · 04/20 19:00
Weekly Report: what happened at TCRX last week (0413-0417)?
Weekly Report · 04/20 09:37
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), KalVista Pharmaceuticals (KALV) and TScan Therapeutics (TCRX)
TipRanks · 04/16 11:01
Weekly Report: what happened at TCRX last week (0406-0410)?
Weekly Report · 04/13 09:38
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 04/09 10:40
TScan Therapeutics to join Needham Virtual Healthcare Conference fireside chat
Reuters · 04/08 11:01
Weekly Report: what happened at TCRX last week (0330-0403)?
Weekly Report · 04/06 09:38
TScan Therapeutics Consolidates Finance Leadership After Officer Resignation
TipRanks · 04/02 12:14
TScan VP Finance Dworak resigns; CFO Amello named principal accounting officer
Reuters · 04/02 11:31
Weekly Report: what happened at TCRX last week (0323-0327)?
Weekly Report · 03/30 09:38
Weekly Report: what happened at TCRX last week (0316-0320)?
Weekly Report · 03/23 09:37
Weekly Report: what happened at TCRX last week (0309-0313)?
Weekly Report · 03/16 09:36
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 03/13 12:05
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB), TScan Therapeutics (TCRX) and Teladoc (TDOC)
TipRanks · 03/12 11:31
Analysts Are Bullish on These Healthcare Stocks: Aligos Therapeutics (ALGS), Demant (WILLF)
TipRanks · 03/11 16:40
Weekly Report: what happened at TCRX last week (0302-0306)?
Weekly Report · 03/09 09:38
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
TipRanks · 03/05 16:29
More
Webull provides a variety of real-time TCRX stock news. You can receive the latest news about Tscan Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TCRX
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.